52/100
Neither HOMA-IR nor diabetic status was significantly associated with tau PET SUVR. 5 key findings →
Participants: 280 Evidence: low
Full summary, score breakdown and related studies → Original source
Research
28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
52/100
First-degree relatives of Alzheimer's disease patients constitute a key population in the search for early markers. 2 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source
This study supports that PET- and CSF-related A/T/N profiles can be used to predict accurately the stages of AD neuropathology. 2 key findings →
Participants: 100 Evidence: low
Full summary, score breakdown and related studies → Original source
Plasma NfL levels might be a promising biomarker for neurodegeneration to discriminate cognitive decline due to AD from other conditions causing cognitive impairment in prodromal stages. 1 key finding →
Participants: 110 Evidence: low
Full summary, score breakdown and related studies → Original source
For the purpose of studying the potential neurobehavioral effects of different human apolipoprotein E (apoE) isoforms produced within the brain, transgenic (TG) mice were generated in which human apoE3 or apoE4 isoforms were under control of an astrocyte-specific, glial fibrillary acidic protein promoter and these TG mice were bred back to apoE knockout (KO) mice. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source
NFL and αSyn oligomers in CSF faithfully differentiate early MSA not only from CON but also from Lewy body synucleinopathies. 2 key findings →
Participants: 24 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Plasma AD biomarkers vary significantly in association with common medical comorbidities as well as ethnicity. 5 key findings →
Participants: 445 Evidence: low
Full summary, score breakdown and related studies → Original source
The light subunit of neurofilament protein (NFL) is a sensitive indicator of central nervous system axonal injury. 1 key finding →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source
For the CSF-based definition of preclinical AD, if a high specificity is required, our data support the use of Aβ42/ttau rather than using Aβ42 in isolation. 3 key findings →
Participants: 38 Evidence: low
Full summary, score breakdown and related studies → Original source
These results suggest that some SAD may involve alternative processing of multiple γ-secretase substrates, raising the possibility that the molecular pathogenesis of SAD might involve γ-secretase dysfunction. 2 key findings →
Participants: 158 Evidence: moderate
Full summary, score breakdown and related studies → Original source
We also explored economic viability of using two different plasma amyloid assays for pre-screening in AD prevention trials and as routine clinical diagnostic tool, versus amyloid PET alone. 4 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source
Alzheimer's disease (AD) is characterized by amyloid beta (Aβ) plaques and hyperphosphorylated tau in the brain. 1 key finding →
Participants: 88 Evidence: low
Full summary, score breakdown and related studies → Original source
Our current results reconfirm and extend the conclusions of the previously published report that the Erlangen Score is a useful tool facilitating interpretation of a complex pattern of the CSF AD biomarkers. 5 key findings →
Participants: 47 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Retrotransposons constitute over 40% of the human genome. 2 key findings →
Design: open-label trial Participants: 12 Evidence: low
Full summary, score breakdown and related studies → Original source
This study provides evidence that CSF metabolites are associated with AD-related pathology, and many of these associations may be causal. 5 key findings →
Participants: 161 Evidence: low
Full summary, score breakdown and related studies → Original source
A newly developed SV2A radiotracer, 18 F-SynVesT-1, was used in this study to investigate synaptic density and its association with Alzheimer's disease (AD) "A/T/N" biomarkers. 2 key findings →
Participants: 97 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Our findings indicate that tau pathology may play a critical role in pathological angiogenesis, contributing to cerebrovascular lesions and neurodegeneration in AD. 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Our results confirmed the diagnostic performance of individual plasma biomarkers Aβ42/Aβ40, p-tau181, NfL, and GFAP in Chinese dementia patients and noted that a combination of these biomarkers may be more accurate in identifying FTD/PSP patients and distinguishing AD from non-AD dementia. 2 key findings →
Participants: 92 Evidence: moderate
Full summary, score breakdown and related studies → Original source
The ratio Aβ42/Aβ40 showed the highest discriminating capacity between AD and non-AD patients and might be useful in clinical practice. 3 key findings →
Participants: 124 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Mean apoJ levels were significantly higher in both MCI and AD groups. 4 key findings →
Participants: 833 Evidence: low
Full summary, score breakdown and related studies → Original source
Plasma biomarkers of neuronal injury and astrogliosis are associated with reduced axonal density and region-specific myelin content. 5 key findings →
Participants: 119 Evidence: low
Full summary, score breakdown and related studies → Original source
Presence of Alzheimer's pathology in patients with RHI/TES is associated with altered cognitive and biomarker profiles. 5 key findings →
Participants: 154 Evidence: low
Full summary, score breakdown and related studies → Original source
Only increased serum NfL concentrations and decreased hippocampal volume was observed in cognitively unimpaired APOEε4 homozygotes compared to non-carriers. 5 key findings →
Participants: 19 Evidence: low
Full summary, score breakdown and related studies → Original source
Olfactory dysfunction can indicate early cognitive decline and is associated with dementia symptoms. 4 key findings →
Participants: 30 Evidence: low
Full summary, score breakdown and related studies → Original source
Infections have been associated with the incidence of Alzheimer disease and related dementias, but the mechanisms responsible for these associations remain unclear. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
From across this tag
10 of the 3,322 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- The contribution of vascular risk factors in neurodegenerative disorders: from mild cognitive impairment to Alzheimer's disease
- Systematic evaluation of urinary formic acid as a new potential biomarker for Alzheimer's disease
- The potential of pathological protein fragmentation in blood-based biomarker development for dementia - with emphasis on Alzheimer's disease
- Cannabinoid CB2 Receptors in a Mouse Model of Aβ Amyloidosis: Immunohistochemical Analysis and Suitability as a PET Biomarker of Neuroinflammation
- Population pharmacokinetic-pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease
- Integrating CSF and EV Proteomes Enhances Biomarker Discovery by Capturing Shared Variation Across Compartments
- Cerebrospinal Fluid Biomarkers of Alzheimer Disease
- Functional connectivity changes in neurodegenerative biomarker-positive athletes with repeated concussions
- Alzheimer's disease biomarkers as predictors of trajectories of depression and apathy in cognitively normal individuals, mild cognitive impairment, and Alzheimer's disease dementia
- Validation of ELISA methods for quantification of total tau and phosporylated-tau181 in human cerebrospinal fluid with measurement in specimens from two Alzheimer's disease studies
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →